Beijing Konruns Pharmaceutical Co.,Ltd. (SHA:603590)

China · Delayed Price · Currency is CNY

28.35

-0.85 (-2.91%)

Oct 14, 2026, 11:30 AM CST

Market Cap	4.45B -44.7%
Revenue (ttm)	917.05M +4.1%
Net Income	170.64M +215.7%
EPS	1.07 +207.9%
Shares Out	157.01M
PE Ratio	27.30
Forward PE	n/a
Dividend	0.35 (1.24%)
Ex-Dividend Date	Jul 8, 2026

Volume	2,096,850
Open	29.02
Previous Close	29.20
Day's Range	28.21 - 29.09
52-Week Range	27.33 - 54.86
Beta	0.40
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 30, 2026

About SHA:603590

Beijing Konruns Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of pharmaceuticals in China and internationally. The company offers agkistrodon halys hemocoagulase under Suling trade name. It is also involved in the development of drug candidates, including ZY5301 that is in phase 3 clinical trials for the treatment of chronic pelvic pain in sequelae of pelvic inflammatory disease; and KC1036, which is in phase 2 clinical trial for the treatment of solid tumors. The company was founded in 2003 and is headqu... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2003

Employees 793

Stock Exchange Shanghai Stock Exchange

Ticker Symbol 603590

Full Company Profile

Financial Performance

In 2025, SHA:603590's revenue was 915.12 million, an increase of 10.87% compared to the previous year's 825.40 million. Earnings were 165.97 million, an increase of 293.13%.

Financial Statements